Mimicking tumor cell heterogeneity of colorectal cancer in a patient-derived organoid-fibroblast model
Author:
Atanasova Velina S, de Jesus Cardona Crhistian, Hejret Vaclav, Tiefenbacher Andreas, Tran Loan, Binder Carina, Mair Theresia, Kabiljo Julijan, Clement Janik, Woeran Katharina, Neudert Barbara, Hengstschläger Markus, Mitterhauser Markus, Müllauer Leonhard, Tichy Boris, Bergmann Michael, Schweikert Gabriele, Hartl Markus, Dolznig Helmut, Egger GerdaORCID
Abstract
AbstractPatient-derived organoid (PDO) cancer models are generated from epithelial tumor cells. Although they reflect the molecular tumor characteristics, they lack the complexity of the tumor microenvironment, which is a key driver of tumorigenesis and therapy response. Here, we present a colorectal cancer (CRC) organoid model that incorporates epithelial cells and stromal fibroblasts from the same patient. Molecular characterization of primary cancer associated fibroblasts (CAFs) and matched normal fibroblasts (NF) revealed proteomic, secretome and gene expression differences in pathways associated with tumor related fibroblast function. Further, CAFs retained higher motility compared to NFs in vitro. Importantly, both CAFs and NFs supported cancer cell proliferation in 3D co-cultures, without the addition of classical niche factors. PDOs grown together with fibroblasts displayed a larger cellular heterogeneity of tumor cells compared to mono-cultures, and closely resembled the in vivo tumor morphology. This was also confirmed by the calculation of cellular proportions of epithelial cell subtypes in organoid mono-versus co-cultures, which were inferred through bioinformatics deconvolution of bulk RNA sequencing data using published single cell RNA sequencing datasets from CRC tissues. Additionally, we observed a mutual crosstalk between tumor cells and fibroblasts in the co-cultures. This was manifested by majorly deregulated pathways such as cell-cell communication and extracellular matrix remodeling in the organoids. For the fibroblasts, we observed enhanced expression of tumor induced marker genes and cytokines characteristic for myo- and immunogenic fibroblasts. This model will be vital as a physiological personalized tumor model to study disease mechanisms and therapy response in CRC.One Sentence SummaryPatient matched fibroblasts support tumor organoid growth in 3D co-culture and maintain intratumoral cellular heterogeneity and histo-morphology.
Publisher
Cold Spring Harbor Laboratory
Reference110 articles.
1. Global patterns and trends in colorectal cancer incidence and mortality 2. J. J. G. Marin , R. I. R. Macias , M. J. Monte , E. Herraez , A. Peleteiro-Vigil , B. S. Blas , P. Sanchon-Sanchez , A. G. Temprano , R. A. Espinosa-Escudero , E. Lozano , O. Briz , M. R. Romero , Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers (Basel) 12, (2020). 3. Patient-Derived Cancer Organoids as Predictors of Treatment Response;Front Oncol,2021 4. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients;NP.J Precis Oncol,2021 5. S. N. Ooft , F. Weeber , K. K. Dijkstra , C. M. McLean , S. Kaing , E. van Werkhoven , L. Schipper , L. Hoes , D. J. Vis , J. van de Haar , W. Prevoo , P. Snaebjornsson , D. van der Velden , M. Klein , M. Chalabi , H. Boot , M. van Leerdam , H. J. Bloemendal , L. V. Beerepoot , L. Wessels , E. Cuppen , H. Clevers , E. E. Voest , Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med 11, (2019).
|
|